胆管癌治疗的现状与进展  

Current status and progress in the treatment of cholangiocarcinoma

作　　者：郑国浩 芶欣 ZHENG Guohao;GOU Xin(Graduate School of Guizhou Medical University,Guiyang 550001,China;Department I of Hepatobiliary Surgery,Guizhou Provincial People's Hospital,Guiyang 550002,China)

机构地区：[1]贵州医科大学研究生院,贵州贵阳550001 [2]贵州省人民医院肝胆外科一部,贵州贵阳550002

出　　处：《中国普通外科杂志》2025年第2期356-364,共9页China Journal of General Surgery

摘　　要：胆管癌(CCA)是一种高度恶性的消化系统肿瘤,由于该疾病的早期临床症状不典型,导致诊断通常较晚,且预后差。近年来,CCA的发病率持续上升,已成为全球重要的肝胆系统恶性肿瘤之一。笔者就CCA的治疗现状与进展作一综述,重点分析了根治性切除、肝移植、姑息性疗法(包括射频消融、介入治疗、免疫治疗、靶向治疗等)和化疗的应用与效果。此外,随着分子靶向药物和免疫治疗的进展,CCA的治疗方案正在逐步优化。尽管目前治疗手段不断创新,但对于中晚期患者,治疗仍然具有挑战性。未来的研究应着力于改善早期诊断技术、开发新型治疗药物,并结合传统医学与现代医学手段,为患者提供更有效的治疗选择。Cholangiocarcinoma(CCA)is a highly malignant digestive system tumor.Due to the non-specific early clinical symptoms of the disease,diagnosis is often delayed,leading to poor prognosis.In recent years,the incidence of CCA has been steadily increasing,making it one of the major malignant tumors of the liver and biliary system globally.This review discusses the current status and progress in the treatment of CCA,focusing on the application and effectiveness of curative resection,liver transplantation,palliative therapies(including radiofrequency ablation,interventional therapy,immunotherapy,targeted therapy,etc.),and chemotherapy.Additionally,with the development of molecular targeted drugs and immunotherapy,treatment strategies for CCA are gradually improving.Although treatment methods continuously evolve,challenges remain in treating patients at advanced stages.Future research should focus on improving early diagnostic technologies,developing new therapeutic drugs,and integrating traditional and modern medical approaches to provide more effective treatment options for patients.

关 键 词：胆管肿瘤 根治性切除 肝移植 姑息疗法 综述 

分 类 号：R735.8[医药卫生—肿瘤]